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Abstract
There is sufficient evidence that the pathological process that causes Parkinson’s disease begins years before the clinical 
diagnosis is made. Over the last 15 years, there has been much interest in the existence of a prodrome in some patients, with 
a particular focus on non-motor symptoms such as reduced sense of smell, REM-sleep disorder, depression, and constipation. 
Given that the diagnostic criteria for Parkinson’s disease depends on the presence of bradykinesia, it is somewhat surpris-
ing that there has been much less research into the possibility of subtle motor dysfunction as a pre-diagnostic pointer. This 
review will focus on early motor features and provide some advice on how to detect and measure them.
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Introduction
The diagnosis of Parkinson´s disease (PD) relies on opera-
tional clinical diagnostic criteria first proposed in 1992 and 
based on clinico-pathological correlation [1]. They require 
the presence of bradykinesia, a progressive reduction in the 
speed and amplitude of repetitive self-willed movements 
(sequence effect), plus at least one further parkinsonian 
sign from rigidity, rest tremor, and/or postural instability 
[1, 2]. By the time an individual fulfils clinical diagnostic 
criteria, at least 40% of nigral dopaminergic neurons have 
been lost [3].
A large number of longitudinal studies support the link 
between several symptoms such as hyposmia, REM-sleep 
behaviour disorder (RBD), constipation, and depression, 
with the subsequent emergence of PD [4]. These non-motor 
clinical features do not necessarily occur in synchrony and 
little is known about their natural course [5], or whether they 
progress at all. Somewhat surprisingly, much less attention 
has been paid to the subtle motor dysfunction that precedes 
overt bradykinesia and a diagnosis of PD [6].
Towards early and timely diagnosis
Several factors may influence a delay in diagnosis even when 
motor signs are evident. These include available and equita-
ble access to healthcare and health professionals, the clini-
cal experience and expertise of those health professional, as 
well as patient comorbidity that may mask or confound the 
clinical impression. In addition to these challenges, there are 
patient-related factors that may lead to a delay in recognition 
of the early motor features of PD. Many patients with PD 
seem to have a visuo-perceptual agnosia to their motor hand-
icap, or attribute changes to tiredness or aging [7]. This can 
result in substantial delays in their initial presentation [8]. 
Upon presentation, clinicians should be willing to discuss 
the possibility of a unifying explanation for the signs that 
others may have noticed. Perceptual agnosia is not limited to 
the motor domain and can occur in the non-motor domains 
as well, since it is not uncommon for patients to have a lack 
of awareness of olfactory dysfunction too [9].
The notion of earlier diagnosis or detection of PD in the 
context of a disease-modifying or neuroprotective interven-
tion is easy to promote. However, given the current absence 
of such interventions, the more relevant issue is what makes 
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a timely diagnosis for patients. Giving a diagnosis before 
any decline in quality of life would arguably not be in most 
patient’s interest and could instead be detrimental [10]. On 
the other hand, for individuals with prominent early non-
motor symptoms, a timely diagnosis may avoid mis-manage-
ment and clinicians should be familiar with these features 
and their treatment [11].
Historic clinical descriptions
Kinnier Wilson was one of the first clinicians to introduce 
the concept of symptoms occurring in the pre-diagnostic 
phase of PD (Kinnier Wilson, Neurology; Volume II, 1940). 
He described the difficulties in detecting the early motor 
signs in older people, where stiffness and slowness could 
be misinterpreted as features of senility. He noted, as did 
James Parkinson, the insidious nature of these symptoms, 
such that patients often struggle to recall the onset. He sug-
gested that slowness and bradykinesia are difficult for the 
patient to detect, but that they frequently precede tremor.
Jean-Martin Charcot had already distinguished bradyki-
nesia as a disabling early clinical feature of PD in many 
cases (Charcot 1872)—“Long before rigidity actually devel-
ops, patients have significant difficulty performing ordinary 
activities […] even a cursory exam demonstrates that their 
problem relates more to slowness in the execution of move-
ment rather than a real weakness”. Separately, William Gow-
ers reported that intermittent tremor could occur years before 
diagnosis (Gowers 1888).
In 1992, Lees described non-specific and sometimes tran-
sient symptoms over a 12-year period before the football 
player Ray Kennedy was eventually diagnosed with PD [8]. 
In this case report, a range of videos recorded from football 
matches were reviewed, and it was observed that during 
matches, Kennedy’s arm was held stiffly and flexed at the 
elbow. This case report together with the finding that nigral 
cell loss probably began at least 5 years before bradykinesia 
was detectable [3], led to a renewed interest in Kinnier Wil-
son’s Parkinson prodrome.
Evidence from observational studies
Clinical cohorts
Healthcare records studies
Despite several methodological drawbacks to retrospective 
studies, the use of routinely collected medical record data 
offers the advantage of studying large numbers of individu-
als. Gonera and colleagues were one of the first groups to 
use this approach in the context of PD [12]. After reviewing 
the medical records of Dutch patients in general practice, 
over a decade prior to PD diagnosis, they suggested that 
prodromal symptoms preceding the diagnosis of PD begin 
up to 6 years before. These findings were in concordance 
with the suggested duration of the presymptomatic phase 
between neuronal loss and the classical syndrome of PD in 
post-mortem studies [3].
Out of 11 million people registered in The UK Health 
Improvement Network (THIN) database, 8166 PD patients 
were compared with 46,455 healthy controls [13]. In addi-
tion to the now-recognised early non-motor features, medical 
codes from clinical consultations were extracted to quan-
tify pre-diagnostic motor markers (symptoms and signs). 
Tremor was the most common motor marker occurring for 
the first time up to 10 years prior to diagnosis, but it was 
not possible to say whether this was a postural/kinetic or 
rest tremor. Balance problems and rigidity were other early 
motor symptoms. Subsequently, the combination of motor 
and non-motor features was used to create a multivariate 
model to derive a 5-year likelihood ratio for later diagnosis 
of PD [14].
Population‑based cohorts
The Rotterdam study is one of the longest running longitu-
dinal studies of PD with 15.8 years of follow-up [15]. Motor 
assessments came from standardised clinical interviews and 
assessments carried out by trained nurses. Subjective com-
plaints were extracted from clinical interviews, including 
stiffness, slowness, tremor, loss of balance, and number of 
falls in the previous year. Bradykinetic features and tremor 
tended to be the earliest motor markers, occurring 7 years 
and 6 years before the diagnosis respectively. In contrast, 
postural features and changes in gait were reported later 
(3.8 years before diagnosis) [15].
The TREND cohort study (Tubinger evaluation of Risk 
factors for Early detection of NeuroDegeneration) recruited 
1046 subjects from the general population. After the first 
screening, individuals with selected non-motor prodromal 
markers (depression, anxiety, and suggestive RBD symp-
toms) were followed up. Motor assessment was based on 
the motor score of Unified Parkinson’s Disease Rating Scale 
(UPDRS) and a list of five potential motor features beyond 
general bradykinesia and rest tremor: sialorrhoea, hypopho-
nia, micrographia, arm swing reduction, and dysarthria. No 
clear differences were found in the motor features occur-
ring in the three different non-motor sub-groups. However, a 
positive relationship between the motor score of the UPDRS 
and the number of non-motor prodromal markers was seen 
[16].
In the Bruneck Study, a group of elderly people were 
assessed at baseline and at 5-year follow-up [17]. Sub-
tle motor signs defined by Movement Disorders Society 
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(MDS)-research criteria using the UPDRS were used as the 
study’s endpoint. Objectively reduced sense of smell and 
hyperechogenicity of the substantia nigra on transcranial 
sonography were linked to subtle motor signs.
Buchman et al. followed up a large group of people with-
out PD [18]. At post-mortem, nigral neuronal loss and the 
presence of Lewy body pathology were correlated with the 
presence of subtle motor signs that had been evaluated with 
an adapted version of UPDRS. An association was found 
only with nigral neuronal loss, but not with Lewy body 
pathology, suggesting that the captured motor signs may be 
more associated with pathological ageing rather than being 
PD-specific. Similar results were demonstrated in another 
post-mortem study in elderly people presenting with mild 
parkinsonian signs and no diagnosis of PD [19].
The PREDICT-PD study looked for subtle motor signs in 
higher and lower risk participants [20]. Risks scores were 
estimated based on the previous identified prodromal mark-
ers and risk factors [21]. All the examinations were recorded 
on video and rated using the MDS-UPDRS together with a 
subjective global impression by two blinded experts. Along-
side raw motor MDS-UPDRS scores, two other clinical 
scales for mild parkinsonian signs were calculated using the 
Louis et al. and Berg et al. definitions [22, 23]. The higher 
risk group had worse scores across all scales compared with 
the lower risk group, with subtle motor changes being pre-
sent in 18–31% in the higher risk group and a higher per-
centage of individuals with a global clinical impression of 
mild parkinsonism [20].
“AT‑RISK” Groups
REM‑sleep behaviour disorder
At least ten prospective studies have demonstrated a strong 
link between idiopathic/isolated RBD and PD, as well as 
some forms of atypical parkinsonism. Mild associated motor 
impairment is the strongest predictive marker of future par-
kinsonism in patients with RBD. In the largest study to date 
that included 1280 patients from different sleep disorder 
centres, motor dysfunction was identified using the Purdue 
Pegboard, alternate-tapping test and timed up-and-go test, 
along with the motor scale of MDS-UPDRS [24]. The aver-
age length of follow-up was 3.6 years, with a maximum of 
19 years. Out of 21 potential parameters of phenoconversion, 
motor impairment was associated with the largest hazard 
ratio (HR: 3) compared to other clinical and neuroimaging 
markers. Motor dysfunction was detected 6–9 years before 
PD diagnosis, with voice changes and facial akinesia being 
reported as the earliest signs (9.8 years), followed by impair-
ment on the Purdue Pegboard and alternating tapping tests 
(8.6 and 8.2 years respectively) [25].
Subtle gait abnormalities and balance problems have 
also been studied in patients with RBD. For example, gait 
patterns were analysed using a sensor carpet (but no body 
sensors so arm swing could not been assessed) in 24 poly-
somnography-confirmed RBD patients and 14 controls [26]. 
During dual tasking (counting backwards, naming as many 
animals as possible, subtracting away 7 from 100), RBD 
patients increased the variability in their step width, and 
demonstrated more asymmetry in step length when asked 
to walk quickly.
Idiopathic anosmia
Only a few small studies of people with confirmed idiopathic 
anosmia have been published. Most rely on an empirical 
definition of hyposmia based on cut-off points on odour 
identification tests such as University of Pennsylvania Smell 
Identification Test (UPSIT) or ‘Sniffin sticks’, with alterna-
tive explanations for impaired olfaction such as nasal sinus 
disease or head trauma being ruled out.
The PARS study (Parkinson Associated Risk Study), in 
which sense of smell was assessed using a self-administered 
UPSIT, found a similar proportion of subtle motor symp-
toms (defined by 2 or more symptoms on the Symptom 
Rating Scale) and average UPDRS motor scores in the nor-
mosmic and hyposmic groups [27]. Dopamine transporter 
(DaT) SPECT imaging was used as the main outcome in 
this study, but subtle motor symptoms at baseline were not 
associated with presynaptic dopaminergic degeneration. 
On the other hand, male gender and constipation, together 
with hyposmia, were associated with reduced dopaminergic 
uptake. In the follow-up phase of the PARS study, patients 
who ‘converted’ to PD had higher UPDRS motor scores than 
the ‘non-converters’ at baseline [28].
Mutation carriers
Glucocerebrosidase (GBA) and leucine-rich repeat kinase 2 
(LRRK2) mutation carriers have a higher age-specific risk of 
PD diagnosis compared with non-carriers (both estimated to 
be about 30% at the age of 80 years) [29–31] .
The prevalence of the LRRK2 G2019S mutation is 
approximately 1% and 4% of sporadic and familial forms 
of PD respectively [32]. LRRK2-related parkinsonism and 
idiopathic PD have similar clinical features and response to 
dopaminergic therapy [33]. However, subtle differences may 
exist with lower overall motor UPDRS scores, a higher pro-
portion with postural instability and action tremor observed 
among LRRK2 mutation carriers with PD [34, 35]. Motor 
signs assessed using the UPDRS appear to be greater in 
non-manifesting carriers of LRRK2 than in non-carriers, and 
also in first-degree relatives of LRRK2 PD cases, indepen-
dently of their mutation status [36, 37]. Using objective gait 
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analysis, carriers show greater variability in gait under chal-
lenging conditions and more obvious arm swing asymmetry 
than controls [38, 39].
In a longitudinal study, whereas motor UPDRS score 
increased over a 4-year period in carriers of LRRK2 muta-
tions, the ones who ‘converted’ to PD did not have signifi-
cantly higher UPDRS motor scores than ‘non-converters’ 
at baseline [40]. Another longitudinal study followed a 
group of carriers of LRRK2 mutations and healthy controls 
for 5 years [41]. The majority of individuals who fulfilled 
the MDS research criteria for probable PD at baseline were 
carriers of LRRK2 mutations, and during follow-up, the ten 
patients who were diagnosed with PD were all carriers [23].
Disease-associated GBA heterozygous variants are com-
mon in PD and are found in 5–10% of patients [42]. Certain 
mutations in the homozygous state are recognised for caus-
ing Gaucher disease [43]. In a longitudinal study of GBA 
homozygous and heterozygous carriers, the UPDRS motor 
score showed greater progression during 6 years of follow-
up in carriers compared to controls [44]. Similarly, two other 
studies compared controls with Gaucher disease patients and 
carriers showing that carriers had a higher score in the motor 
UPDRS than the other groups [45, 46].
Defining motor prodromes
Bradykinesia
Bradykinesia is the only physical sign that is present in every 
patient with PD, using current definitions, and the only car-
dinal sign that has been correlated with cell loss in the pars 
compacta of the substantia nigra. Bradykinesia is related to 
a failure in the recruitment of cortical motor neurons during 
an intended task [47]. The more complex the action is (i.e., 
performing different actions simultaneously), the easier it 
will be to detect bradykinesia.
It is often described by patients as clumsiness or weak-
ness when carrying out delicate tasks [8]. Questions should 
be directed towards loss of dexterity in repetitive manual 
tasks such as buttoning clothes, shaving, beating eggs, sham-
pooing, stirring, or writing, and when possible close family 
members should also be asked whether they have noticed 
any subtle changes (Table 1).
Tremor
Beyond recognising that tremor may be transient and pre-
date the other features of PD, William Gowers made another 
key observation—‘In the early stage, only an apparent inter-
mission of contraction is recognised, either in rest or on 
movement’ (Gowers 1888) [48]. This intermission before 
the emergence of tremor is readily recognisable in clinical 
practice and helps to distinguish a postural tremor in PD 
from that seen in familial essential tremor.
A monosymptomatic rest tremor without bradykinesia 
has been associated with dopamine denervation on dopa-
mine transporter imaging in some patients and all of these 
cases go on to develop PD. Other studies have indicated that 
longstanding asymmetrical postural tremor could be a pre-
dictive factor for development of PD and others have argued 
that even bilateral essential tremor could be a risk factor for 
PD [49, 50]. Of note, a significant number of patients with 
‘benign tremulous Parkinsonism’ have a family history of 
tremor and/or PD [51, 52].
Neuropathological studies comparing patients with 
confirmed PD and those with a slowly progressive tremor-
dominant parkinsonism suggest that there is less nigral cell 
loss in the latter [53]. The authors discussed the importance 
of follow-up for elderly patients with late onset of essential 
tremor, since parkinsonism may emerge ultimately [53].
Posture
A stiff-arm held flexed at elbow and the fingers in a flexed-
adduction position are tell-tale signs for early parkinsonism. 
Patients can also appear preternaturally still; maintaining 
the same position for long periods without the small fidgets 
and adjustments that healthy people make when sitting or 
standing (Kinnier Wilson, 1940). In young-onset PD, brad-
ykinesia is not infrequently preceded by foot dystonia and 
occasionally writer’s cramp by several years. A few patients 
present with a motor restlessness related to difficulty finding 
a comfortable posture in which to rest.
Gait
Walking is an automated, rhythmic motor task that requires 
both motor and executive skills [54, 55]. The gait pattern 
is defined by arm swing (amplitude and symmetry), stride 
(length, off-ground elevation), and coordination between 
Table 1  Symptoms first noticed by patients
Handwriting changes: progressively smaller, cramped, sloping
Dry eyes due to reduced blinking
Lack of facial expression: distracted, vacant, blank (often reported by 
relatives and friends)
Lack of arm swing (reported by relatives and friends)
Frozen shoulder
Lack of manual dexterity in repetitive tasks: beating eggs, shaving, 
typing, playing an instrument
Painful abnormal posture in their foot (typically in young-onset PD)
Scuffing the sole or heel of one foot when walking
Feeling of imbalance
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four limbs (rhythm and smoothness). In the elderly, mus-
culoskeletal disorders and the motor signs of diffuse cer-
ebrovascular disease need to be distinguished from true 
parkinsonism.
Step-to-step variability, decreased amplitude of arm 
swing or arm swing asymmetry, and reduction in the 
‘smoothness’ of gait may be early signs of a Parkinsonian 
syndrome [56–58].
Several approaches to quantification of gait analysis have 
been used, from the “timed up-and-go” test, to more sophis-
ticated analysis using sensors. The “timed up-and-go” test 
is a simple test which has been used to measure mobility 
and risk of falls in PD and elderly people [59]. However, its 
applicability as an early motor marker in PD has not been 
studied in detail.
In the early stages of PD, compensatory mechanisms 
may prevent gait disturbances. Dual tasking (i.e., asking 
the patient to do mental arithmetic while walking) is a use-
ful clinical method to unmask subtle signs [60, 61]. This 
strategy has been used to study people at risk of developing 
PD, such as non-manifesting carriers of LRRK2 mutations 
and people with hyperechogenicity of the substantia nigra. 
The most characteristic gait patterns found in the at-risk 
groups under challenging conditions were: higher stride 
time variability, arm swing asymmetry, and decrease in the 
smoothness of trunk rotation [38, 57, 60]. Reduction in the 
smoothness in axial swaying could be due to an increase in 
axial rigidity, such as that which happens with limb rigidity 
during distraction tasks (i.e., Froment´s manoeuvre).
Since the prevalence of PD increases with age and gait 
abnormalities are common in the elderly population, it is 
important to consider the effects of aging as a confounding 
factor and consider multifactorial effects of aging on gait 
from those of PD [62]. Mirelman and colleagues studied 60 
healthy controls aged between 30 and 77 years. Whereas arm 
swing amplitude decreased with age and a dual task, arm 
swing asymmetry and limb coordination (stepping consist-
ency and rhythm) appeared to be less susceptible to aging 
[63].
Handwriting and typing
Handwriting is a fine motor task that imposes a substantial 
demand on cognition [64]. The concept of handwriting dif-
ficulties as an early motor feature of PD dates back to 1817 
when James Parkinson documented handwriting changes 
preceding impairment in walking. Schwab demonstrated 
that micrographia could be present 4 years earlier than PD 
diagnosis by reviewing serial signatures from cheque stubs 
of patients prior to them developing the classical features 
of PD [65].
Micrographia is defined by gradual reduction in letter size 
and has been proposed by some as a relevant clinical bio-
marker [66]. The script is often crabby and cramped, and in 
right handers tends to slope upwards.
In recent years, with the exploration of technologies to 
measure objectively handwriting abnormalities in parkinson-
ism, the term dysgraphia has been introduced to embrace not 
only script size but other kinetic variables such as fluency, 
velocity, and duration. This may offer the possibility of pick-
ing up more abnormalities in the script of people with PD in 
an early stage [64]. It is also of note that there is very little 
correlation between micrographia and bradykinesia severity 
in PD [67].
The kinematics of typing have also been tracked remotely 
in de novo patients with PD from the initiation of dopa-
minergic treatment [68]. The investigators from this study 
observed that improvement in typing kinematic parameters 
occurred earlier than in motor scores on the UPDRS after 
commencing treatment.
Voice
Hypokinetic dysarthria is a characteristic speech pattern in 
PD, which is defined by hypophonia, lack of voice modu-
lation, poor articulation, hesitations, and stoppages [69]. 
Although it has been argued that dysarthria may be an early 
motor sign, voice changes have received little attention 
[70]. Researchers working on the Oxford Discovery Par-
kinson’s Cohort have used a smartphone app and machine 
learning to distinguish patients with PD, RBD, and controls 
[71]. Voice analysis was part of the test battery which also 
included balance, gait, finger tapping, reaction time, and 
tremor assessment. They instructed participants to perform 
a sustained phonation (“aaah”) as long as they can. Vibration 
parameters (amplitude and frequency) were analysed to find 
instabilities of the vocals folds oscillating patterns. Along 
with tremor, voice was found to be the most distinguishing 
feature between the three groups, with voice being the most 
discriminatory factor between RBD and controls. The same 
team has demonstrated how this approach could be used to 
predict the milestones of progression in PD [72]. Another 
study focused on abnormal speech patterns in prodromal PD, 
showing that voice frequency variability could be detected 
up to 5 years prior the diagnosis [73].
Blink rate and facial hypomimia
The standard rate of blinking can range between 14 and 25 
blinks per minute. It is influenced by mental tasks (reading, 
watching a film, and speaking) and also mental state (anxiety 
and depression). Several studies have proved a positive asso-
ciation between blinking rate and central levels of dopamine 
by comparing conditions with inverse dopamine activity (PD 
 Journal of Neurology
1 3
and schizophrenia) and testing the effect of dopamine ago-
nists and antagonists on eye-blink rate [74].
Relatives and friends often notice a frozen facial expres-
sion which they describe as a dullness, a ‘poker face’, ‘a 
mask’, a sadness, or a coldness. A reduction of blink rate 
as a feature of PD has long been recognised—‘A valuable 
early symptom is infrequent blinking of the eyelids’ (Kinnier 
Wilson 1940). This may lead to a complaint of dry sore eyes 
or watering of the eyes. However, Fitzpatrick and colleagues 
could not find any link between blink rate and disease sever-
ity and duration in one study, which led to the conclusion 
that reduced blink rate is an early and unalterable feature of 
PD [75].
Subthreshold parkinsonism vs normal aging
Approximately 30–40% of elderly people without a known 
neurological condition exhibit ‘soft’ basal ganglia (extrapy-
ramidal) signs on clinical examination, including slowness, 
postural changes, and gait problems [22, 62] (Table 2). Most 
of these patients do not have early PD and the signs can be 
attributed to old age, diffuse cerebrovascular disease, and 
musculoskeletal problems [76, 77].
Vascular disease and risk factors, in particular the com-
bination of diabetes mellitus and heart disease, have been 
shown to increase the probability of parkinsonian signs by 
70% [77]. Bennet and colleagues showed that people with 
subclinical parkinsonian signs had a risk of mortality twice 
as high as those without it [62].
Some clues from the examination can be extracted to 
differentiate normal ageing from PD. The most important 
one is that in general, the progression of symptoms in PD 
is quicker than that which occurs due to ageing. Asymme-
try between sides, the sequence effect on finger tapping, 
hypomimia, changes in voice modulation, and the presence 
of other non-motor symptoms are all helpful in distinguish-
ing the pre-diagnostic stages of PD from the effects of aging 
[78].
Methods of identifying subtle motor 
abnormalities
Motor analysis in the early phases of PD has several limita-
tions. Heterogeneity in prodromal phenotypes may make it 
difficult to standardise methods of analysis. As mentioned, 
with clinical rating scales, parkinsonian signs have been 
described in between 30 and 40% of the elderly population 
without PD [62]. No consensus exists on the ideal method 
of measuring motor dysfunction in the early stages of PD, 
including which scales to use, which kinetic parameter are 
best to analyse (e.g., amplitude or velocity for bradykinesia), 
and under what conditions (home monitoring, lab or clinic 
environment, and challenging conditions). Standardised 
approaches may be required to set the boundaries between 
prodromal and established PD [79].
Extranigral structures may play a compensatory role in 
the progressive dopamine loss in PD [80]. At early stages, 
such mechanisms are strong enough to mask such motor 
deficits. Thus, as outlined in some of the aforementioned 
studies, clinical examination and assessment should aim to 
challenge compensatory mechanisms (Fig. 1) [6].
Questionnaires
Questionnaires asking about subjective motor complaints 
have been used as a diagnostic tool with apparent high sen-
sitivity and specificity [81]. However, the role of bias in 
reporting subjective symptoms has to be considered [82].
Telephone questionnaires have been used to study 
patients’ perception of prodromal symptoms [83]. In one 
study, slowing of fine hand movements, general bradykine-
sia, dysarthria, and reduced arm swing were noticed between 
2.2 and 4.7 years before the patient fulfilled the diagnostic 
criteria of PD. Although PD patients reported motor dif-
ficulties more frequently, 10% of age-matched controls had 
Table 2  Features of ageing as opposed to Parkinsonism
Isolated shuffling broad-based gait
General slowness not particularly affecting dexterity
Quivering tremulous voice
Unsteadiness with falls
No response to levodopa
Fig. 1  On the left, features to explore on normal condition (spontane-
ous movements). On the right, other signs emerge under challenging 
conditions (dual tasking and fast walking)
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also noticed some changes in their dexterity and speed of 
movement.
Maraki and colleagues used a motor screening battery, 
including a questionnaire focused on gait and postural dif-
ficulties in elderly people taking part of the HELIAD study 
(Hellenic Longitudinal Investigation of Aging and Diet 
cohort). Having at least one subjective gait/postural dif-
ficulty increased the probability of having prodromal PD 
(based on the MDS research criteria) [23]. Difficulty walk-
ing outdoors, poor balance, using a walking aid, and the 
presence of a shuffling gait were reported more commonly 
(between 25 and 35%) by subjects with probable prodromal 
PD [84].
Clinical scales
The standard of motor assessment for established PD is the 
MDS-UPDRS [23]. It is a semi-quantitative scale based on 
several motor tasks such as rapid simple movements (finger 
and toe tapping test) addressed to evaluate bradykinesia.
However, it is important to note that the UPDRS was not 
designed for use in the prodromal stages of PD, and may not 
be sensitive enough to pick up subtle motor features at early 
stages [6]. The MDS research criteria for prodromal PD 
recommends a cut-off of 6 (overall score) and 3 (excluding 
action tremor) for defining subthreshold parkinsonism [23]. 
In one study, bradykinesia-related items presented the lowest 
reliability of all the UPDRS parameters with a finger-tapping 
interrater reliability Kappa coefficient below 0.50 [85].
At the prodromal stages of PD, the scoring used in the 
MDS-UPDRS is susceptible to a floor effect between scores 
of 0 and 1 (normal and slight abnormalities). To rectify this 
limitation, a modified bradykinesia score was created which 
separately score three kinetic parameters (frequency, rhythm, 
and amplitude) for each movement [86]. However, even with 
these modifications, there are additional important features 
such as manual dexterity, posture, and gait under challenging 
conditions that are not captured.
Technology
There has been considerable interest in technological solu-
tions to the capture of subtle motor features of PD. However, 
a reliance on technology, including artificial intelligence 
along with machine and deep learning, and other ‘big data’ 
approaches, can lead to oversimplification and loss of appre-
ciation for the particularities and subtleties of the motor fea-
tures of PD. The clinician’s observations and perception and 
the evaluation of a patient’s co-morbidities are essential to 
avoid misdiagnosis.
Technological approaches can be classified accord-
ing to whether the assessments are home or lab-based, the 
type of device (body sensors, smartphone app, 3D motion 
capture, and computer keyboard), and kind of movement 
tested (gait, finger-tapping, handwriting, and spiral drawing) 
(Fig. 2). One important question is whether, particularly in 
the prodrome, technology should be validated against scales 
used for established PD, or whether new scoring paradigms 
should be prioritised [87]. There is now the emerging pos-
sibility that ‘big data’ approaches will help define new sub-
groups of patients based on both motor and non-motor fea-
tures and other clinical characteristics, making us less reliant 
on the traditional scales [88]. While technology will cer-
tainly play a far greater role in the assessment and manage-
ment of PD, it remains hard to envisage how it could wholly 
replace a detailed neurological examination, appreciation 
of the complex, and heterogeneous motor and non-motor 
manifestations of PD and clinical expertise.
Conclusion
Subtle motor dysfunction is an important but relatively 
neglected part of the prodromal phase of PD. In contrast 
to individual non-motor features, by current definition, all 
patients with PD will develop early motor signs, and motor 
dysfunction will progress as the disease advances. It is clear 
Fig. 2  New technology era. The importance of combining clinical 
expertise with more sophisticated quantitative tools. 1: Body sen-
sors with incorporated accelerometers able to monitor movement in 
a home-environment. 2: Smartphone-based tools to assess bradykin-
esia, tremor, and voice modulation. 3: Keyboard typing test to quan-
tify velocity and rhythm during the task. 4: Digital sensors associ-
ated with a gyroscope to quantify changes in velocity, amplitude, and 
rhythm during finger tapping. 5: Digital screen and sensory pen for 
the handwriting and spiral drawing assessment
 Journal of Neurology
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that available questionnaires and clinical scales are not suit-
ably adapted for early stages of PD, and electronic measures 
are not currently sufficiently developed and validated. New 
ways and measures are still needed to reliably pick up motor 
dysfunction at the earliest stage.
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